A cell type selective YM155 prodrug targets receptor-interacting protein kinase 2 to induce brain cancer cell death
Glioblastoma (GBM) is the most prevalent and aggressive primary central nervous system
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …
A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death
TJ West, J Bi, F Martínez-Peña, EJ Curtis… - Journal of the … - pubmed.ncbi.nlm.nih.gov
Glioblastoma (GBM) is the most prevalent and aggressive primary central nervous system
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …
A Cell Type Selective YM155 Prodrug Targets Receptor-Interacting Protein Kinase 2 to Induce Brain Cancer Cell Death.
TJ West, J Bi, F Martínez-Peña, EJ Curtis… - Journal of the …, 2023 - europepmc.org
Glioblastoma (GBM) is the most prevalent and aggressive primary central nervous system
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …
(CNS) malignancy. YM155 is a highly potent broad-spectrum anti-cancer drug that was …